publication venue for
- Optimizing antithrombotic therapy in patients with coexisting cardiovascular and gastrointestinal disease. 21:574-592. 2024
- The need for increased pragmatism in cardiovascular clinical trials. 19:737-750. 2022
- Increasing representation and diversity in cardiovascular clinical trial populations. 18:537-538. 2021
- Dual-pathway inhibition for secondary and tertiary antithrombotic prevention in cardiovascular disease. 17:242-257. 2020
- Reversal agents for non-vitamin K antagonist oral anticoagulants. 15:273-281. 2018
- Management of atrial high-rate episodes detected by cardiac implanted electronic devices. 14:701-714. 2017
- Reperfusion strategies in acute myocardial infarction and multivessel disease. 14:665-678. 2017
- Perioperative anticoagulation—are we at 'a bridge too far'?. 12:133-134. 2015
- Direct thrombin inhibitors in cardiovascular disease. 9:402-414. 2012
- Dabigatran and risk of myocardial infarction. 9:260-262. 2012
- Effective communication and ethical consent in decisions related to ICDs. 8:694-705. 2011
- New antithrombotic agents—insights from clinical trials. 7:498-509. 2010
- A natural way to cardiovascular health. 7:1-2. 2010
- The need to test the theories behind the Polypill: rationale behind the Indian Polycap Study. 6:96-97. 2009
- Platelet ADP-receptor antagonists for cardiovascular disease: past, present and future. 5:766-780. 2008
- APOA5 genetic variants are markers for classic hyperlipoproteinemia phenotypes and hypertriglyceridemia. 5:730-737. 2008
- Re-examining aggressive anticoagulant therapy: the case of acute coronary syndromes. 5:72-73. 2008
- Is 3 months the optimum duration of anticoagulation therapy for deep vein thrombosis and pulmonary embolism?. 4:472-473. 2007
- OASIS-6: should patients with acute ST-segment elevation myocardial infarction be treated with fondaparinux?. 3:478-479. 2006
- Can fondaparinux safely prevent the occurrence of venous thromboembolism in acutely ill medical patients?. 3:358-359. 2006
- Does clopidogrel provide additional benefit to aspirin and fibrinolytic therapy in patients after STEMI?. 2:500-501. 2005
- Should patients with stable coronary artery disease be treated with ACE inhibitor therapy?. 2:124-125. 2005